G.D. Tomaras

Type de document

Articles (14)

Co-auteur

Date

Source

Mot-clé

SIDA (11) Human beings (11) anticorps (10) procès (10) Vaccination (10) Vaccination (10) protéine (9) Immunoglobulins (9) ADN (8) Vaccines (8) Immunoglobulin G (8) DNA (8) virus (7) adulte (6) Immunization (6) Antigens (6) adulte (6) puits (5) sécurité (5) dosage (5) vecteur (5) Development (5) Trials (5) risque (4) immunité (4) gène (4) méthode (4) Control (4) Immunodeficiency (4) Rates (4)

Documents écrit par G.D. Tomaras (14) | parle de G.D. Tomaras (0)

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
K.W. Cohen et al. (15 févr. 2023)
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans.
K.E. Seaton et al. (15 avr. 2021)
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
M.C. Hosseinipour et al. (23 janv. 2021)
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
Y. Lévy et al.
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Z. Moodie et al.
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.
M. Esteban et al. (27 déc. 2019)
Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01.
D. Pinto et al. (13 nov. 2019)
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.
N.G. Rouphael et al. (1 nov. 2019)
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
G. Pantaleo et al.
Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
J.A. Cram et al. (2019)
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
N.L. Yates et al. (15 avr. 2018)
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.
G. Zurawski et al. (2016)
COMPASS identifies T-cell subsets correlated with clinical outcomes.
L. Lin et al.
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.
J.D. Fuchs et al. (2015)